$TXG News

10x Genomics (TXG) Stock Fair Value Rises After Analysts Back AI And Atera Demand

3 Reasons to Sell TXG and 1 Stock to Buy Instead

10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026

TD Cowen Maintains Hold on 10x Genomics, Raises Price Target to $70

Morgan Stanley Maintains Equal-Weight on 10x Genomics, Raises Price Target to $70

Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $100

Why Are 10x Genomics (TXG) Shares Soaring Today

Is 10x Genomics (TXG) Using Its Fred Hutch Oncology Alliance To Redefine Its Clinical Moat?

10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research

10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers

Barclays Maintains Overweight on 10x Genomics, Raises Price Target to $110

10x Genomics Partners With Fred Hutchinson Cancer Center Over Use Of Single Cell, Spatial Technologies In Both Solid Tumor And Hematologic Malignancies

10x Genomics (TXG) Starts Atera Shipments And Sentira, Is The Upside Already Priced In?

10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises

10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions

10x Genomics Begins Global Shipments of Atera, Putting Unprecedented Spatial Biology Capabilities in Researchers' Hands

Leerink Partners Maintains Market Perform on 10x Genomics, Raises Price Target to $90

10x Genomics Begins Commercial Shipments Of Its Transcriptome Analysis Tool Atera

10x Genomics Launches NVIDIA-Accelerated Sentira Spatial Analysis, Cutting Spatial Data Processing Times From Hours To Minutes

10x Genomics (TXG) Stock Is Up, What You Need To Know